Skip to main content

Advertisement

SpringerLink
Log in

Variations of serum levels of adiponectin and resistin in chronic viral hepatitis

  • Original Article
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Background and aims: Several studies investigated the possible role of adipokines during chronic viral hepatitis, not producing defined results neither clearly establishing their behavior in course of anti-viral treatment. Our study evaluated blood concentrations of adiponectin and resistin in patients with chronic hepatitis C (CHC), B (CHB), and D (CHD) receiving anti-viral treatment, at baseline and after therapy. Methods: We examined 122 subjects, divided into two groups: 64 patients with chronic hepatitis C virus (HCV) infection (38 males and 26 females, mean age 47.25 yr) and 58 patients including 39 ones with chronic hepatitis B virus (HBV) infection (26 males and 13 females, mean age 48.46 yr) and 19 ones with chronic HBV-hepatitis D virus (HDV) infection (15 males and 4 females, mean age 45.79 yr). Serum levels of adiponectin and resistin were assayed by enzyme-linked immunosorbent assay. Results: In the group of CHC patients we observed a significant decrease in resistin after therapy (p=0.006), while not a significant increase in adiponectin after treatment (p=0.32). Evaluation of changes in adiponectin and resistin levels after anti-viral treatment, both in responders and non-responders, revealed no significant variations. In the group of HBV+ and HBV-HDV+ patients, we found a decrease in resistin after therapy (p=0.0016) and a not significant reduction in adiponectin after treatment (p=0.13). Furthermore, we noticed a significant reduction of resistin (p=0.006) in the sub-group of responders. Conclusions: Our data suggested the possible marker role of adiponectin and resistin in the inflammatory process in course of chronic viral hepatitis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Alter HJ, Seeff LB: Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis 2000, 20: 17–35.

    Article  PubMed  Google Scholar 

  2. World Health Org. Hepatitis B, Fact Sheet No 204. Geneva: World Health Organization, 2000.

    Google Scholar 

  3. Tsai SM, Lin SK, Lee KT, et al. Evaluation of redox statuses in patients with hepatitis B virus-associated hepatocellular carcinoma. Ann Clin Biochem 2009, 46: 394–400.

    Article  PubMed  Google Scholar 

  4. Mohamadkhani A, Jazii FR, Poustchi H, et al. The role of mutations in core protein of hepatitis B virus in liver fibrosis. Virol J 2009, 6: 209.

    Article  PubMed Central  PubMed  Google Scholar 

  5. Rabe K, Lehrke M, Parhofer KG, Broedl UC. Adipokines and insulin resistance. Mol Med 2008, 14: 741–51.

    Article  PubMed Central  PubMed  Google Scholar 

  6. Bertolani C, Marra F. The role of adipokines in liver fibrosis. Pathophysiology 2008, 15: 91–101.

    Article  PubMed  Google Scholar 

  7. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 2006, 116: 1784–92.

    Article  PubMed Central  PubMed  Google Scholar 

  8. Marra F, Bertolani C. Adipokines in liver diseases. Hepatology 2009, 50: 957–69.

    Article  PubMed  Google Scholar 

  9. Matsuzawa Y, Funahashi T, Kihara S, Shimomura I. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol 2004, 24: 29–33.

    Article  PubMed  Google Scholar 

  10. Yamauchi T, Kamon J, Ito Y, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003, 423: 762–9.

    Article  PubMed  Google Scholar 

  11. Powell EE, Jonsson JR, Clouston AD. Steatosis: co-factor in other liver diseases. Hepatology 2005, 42: 5–13.

    Article  PubMed  Google Scholar 

  12. Gustafson B, Hammarstedt A, Andersson CX, Smith U. Inflamed adipose tissue: a culprit underlying the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol 2007, 27: 2276–83.

    Article  PubMed  Google Scholar 

  13. Bo S, Ciccone G, Durazzo M, Gambino R, Massarenti P, Baldi I Efficacy of antioxidant treatment in reducing resistin serum levels: a randomized study. PloS Clin Trials 2007, 2: e17.

    Article  PubMed Central  PubMed  Google Scholar 

  14. Myers MG, Cowley MA, Münzberg H. Mechanisms of leptin action and leptin resistance. Annu Rev Physiol 2008, 70: 537–56.

    Article  PubMed  Google Scholar 

  15. Bertolani C, Sancho-Bru P, Failli P, et al. Resistin as an intrahepatic cytokine: over-expression during chronic injury and induction of proinflammatory actions in hepatic stellate cells. Am J Pathol 2006, 169: 2042–53.

    Article  PubMed Central  PubMed  Google Scholar 

  16. Petta S, Camma C, Di Marco V, et al. Retinol-binding protein 4: a new marker of virus-induced steatosis in patients infected with hepatitis c virus genotype 1. Hepatology 2008, 48: 28–37.

    Article  PubMed  Google Scholar 

  17. Marchesini G, Moscatiello S, Di Domizio S, Forlani G. Obesity-associated liver disease. J Clin Endocrinol Metab 2008, 93: S74–80.

    Article  PubMed  Google Scholar 

  18. Musso G, Gambino R, Durazzo M, et al. Adipokines in NASH: postprandial lipid metabolism as a link between adiponectin and liver disease. Hepatology 2005, 42: 1175–83.

    Article  PubMed  Google Scholar 

  19. Floreani A, Variola A, Niro G, et al. Plasma adiponectin levels in primary biliary cirrhosis: a novel perspective for link between hypercholesterolemia and protection against atherosclerosis. Am J Gastroenterol 2008, 103: 1959–65.

    Article  PubMed  Google Scholar 

  20. Durazzo M, Niro G, Premoli A, et al. Type 1 autoimmune hepatitis and adipokines:new markers for activity and disease progression? J Gastroenterol 2009, 44: 476–82.

    Article  PubMed  Google Scholar 

  21. Sato S, Furuta K, Mishiro T, et al. Serum adiponectin concentration in patients with hepatitis C virus. J Clin Gastroenterol 2005, 39: 744–5.

    Article  PubMed  Google Scholar 

  22. Grigorescu M, Radu C, Crisan D, et al. Metabolic syndrome, insulin resistance and adiponectin levels in chronic hepatitis C. J Gastrointestin Liver Dis 2008, 17: 147–54.

    PubMed  Google Scholar 

  23. Zografos TA, Liaskos C, Rigopoulou EI, et al. Adiponectin: a new independent predictor of liver steatosis and response to IFN-alpha treatment in chronic hepatitis C. Am J Gastroenterol 2008, 103: 605–14.

    Article  PubMed  Google Scholar 

  24. Palmer C, Hampartzoumian T, Lloyd A, Zekry A. A novel role for adiponectin in regulating the immune responses in chronic hepatitis C virus infection. Hepatology 2008, 48: 374–84.

    Article  PubMed  Google Scholar 

  25. Lo Iacono O, Venezia G, Petta S, et al. The impact of insulin resistance, serum adipocytokines and visceral obesity on steatosis and fibrosis in patients with chronic hepatitis C. Alim Pharmacol Ther 2007, 25: 1181–91.

    Article  Google Scholar 

  26. Yagmur E, Tratwein C, Gressner AM, Tacke F. Resistin serum levels are associated with insulin resistance, disease severity, clinical complications and prognosis in patients with chronic liver diseases. Am J Gastroenterol 2006, 101: 1244–52.

    Article  PubMed  Google Scholar 

  27. Tiftikci A, Atug O, Yilmaz Y, et al. Serum levels of adipokines in patients with chronic HCV infection: relationship with steatosis and fibrosis. Arch Med Res 2009, 40: 294–8.

    Article  PubMed  Google Scholar 

  28. Tacke F, Wüstefeld T, Horn R, et al. High adiponectin in chronic liver disease and cholestasis suggests biliary route of adiponectin excretion in vivo. J Hepatol 2005, 42: 666–73.

    Article  PubMed  Google Scholar 

  29. Siagris D, Vafiadis G, Michalaki M, et al. Serum adiponectin in chronic hepatitis C and B. J Viral Hepat 2007, 14: 577–83.

    Article  PubMed  Google Scholar 

  30. Liu CJ, Chen PJ, Lai MY, et al. High serum adiponectin correlates with advanced liver disease in patients with cronic hepatitis B virus infection. Hepatol Int 2009, 3: 364–70.

    Article  PubMed Central  PubMed  Google Scholar 

  31. Hui CK, Zhang HY, Lee NP, et al. Serum adiponectin is increased in advancing liver fibrosis and declines with reduction in fibrosis in chronic hepatitis B J Hepatol 2007, 47: 191–202.

    Article  PubMed  Google Scholar 

  32. Wong VW, Wong GL, Yu J, et al. Interaction of adipokines and hepatitis B virus on histological liver injury in the Chinese. Am J Gastroenterol 2010, 105: 132–8.

    Article  PubMed  Google Scholar 

  33. Degawa-Yamauchi M, Bovenkerk JE, Juliar BE, et al. Serum resistin (FIZZ 3) protein is increased in obese humans. J Clin Endocrinol Metab 2003, 88: 5452–5.

    Article  PubMed  Google Scholar 

  34. McTernan PG, Fisher FM, Valsamakis G, et al. Resistin and type 2 diabetes: regulation of resistin expression by insulin and rosiglitazone and the effects of recombinant resistin on lipid and glucose metabolism in human differentiated adipocytes. J Clin Endocrinol Metab 2003, 88: 6098–106.

    Article  PubMed  Google Scholar 

  35. Tsochatzis E, Papatheodoridis GV, Hadziyannis E, et al. Serum adipokine levels in chronic liver diseases: association of resistin levels with fibrosis severity. Scand J Gastroenterol 2008, 43: 1128–36.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, University of Turin, C.so A.M. Dogliotti 14, 10126, Turin, Italy

    M. Durazzo, P. Belci, A. Collo, E. Grisoglio, V. Ambrogio, M. Spandre, R. Gambino, M. Cassader & S. Bo

  2. Department of Gastroenterology, Hospital Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy

    G. Niro & R. Fontana

Authors
  1. M. Durazzo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. Belci
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G. Niro
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Collo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. E. Grisoglio
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. V. Ambrogio
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M. Spandre
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. R. Fontana
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. R. Gambino
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. M. Cassader
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. S. Bo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Durazzo.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Durazzo, M., Belci, P., Niro, G. et al. Variations of serum levels of adiponectin and resistin in chronic viral hepatitis. J Endocrinol Invest 36, 600–605 (2013). https://doi.org/10.3275/8883

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.3275/8883

Key-words

Search

Navigation